FDA approves Olysio/Sovaldi combo for HCV

FDA approved the combination of Olysio simeprevir from Johnson & Johnson (NYSE:JNJ) and Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) to treat chronic HCV genotype 1 infection. The combination is the second all-oral therapy approved to treat HCV-1 that does not require interferon or ribavirin. Gilead's Harvoni, which combines its ledipasvir with Sovaldi, was approved in October.

The recommended course of treatment for both combos is 12 weeks for patients without cirrhosis, and 24 weeks for those with cirrhosis. ...